National Institute of Child Health and Human Development
Maternal Fetal Medicine Units Network

MFMU Network Randomized Clinical Trial of
Omega-3 Supplementation To Prevent Preterm Birth

Objective

To determine whether Omega-3, in conjunction with 17P injections, reduces the risk of preterm birth in women at high risk for spontaneous preterm delivery.

Conclusion

An omega-3 LCPUFA supplement provided no additional benefit for prevention of recurrent preterm birth among women receiving 17-OHPC.

Clinical Centers

Major Eligibility Criteria

• Gestational age 16-21 weeks
• Singleton pregnancy
• Previous preterm delivery
• Informed consent

Groups

• Omega-3 supplement
• Daily placebo supplement

Management Protocols

• Coded medication:
• Daily Omega-3 supplement of placebo until delivery or 37 weeks, whichever comes first

Outcome Measures

• Primary:
• Preterm delivery (< 37 weeks gestation)
• Secondary:
• Composite neonatal outcome

Return to Top